← Back to patent-cliff list
RGRN-305
Tier C — Watch / tradeRGRN-305
Curis Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：HSP90
Indications (approved)：Hidradenitis suppurativa, Plaque psoriasis, 坏疽性脓皮病, Non-small cell lung cancer, Psoriasis, Lymphoma, Solid tumour
Regional status
US
-
2024-05-13
EU
Phase II
2023-10-01
China
Phase I
2022-08-30
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of RGRN-305?
Approved indications include: Hidradenitis suppurativa, Plaque psoriasis, 坏疽性脓皮病, Non-small cell lung cancer, Psoriasis, Lymphoma, Solid tumour.
When does the RGRN-305 patent expire?
No public expiry year is available for RGRN-305 yet; this page updates once verified.
How do I get a quote for RGRN-305 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02